RxDoctor Payments Data

Brian Sorin, MD

Neurology · Plano, TXNPI 1932229911

Payments from drug & device makers

$103,280in general payments, 2019–2025

Across 1,124 payments — averaging $91.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ipsen Innovation$50K
  • Amgen$20K
  • Teva Pharmaceuticals USA, Inc.$9K
  • Ipsen Biopharmaceuticals, Inc$9K
  • AbbVie$4K
  • Lundbeck LLC$2K
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$16,20040%
  • Speaking & faculty fees$1,1903%
  • Travel & lodging$2,5566%
  • Food & beverage$20,94851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ipsen Innovation44$49,917
Amgen(2 entities)188$19,687
Teva Pharmaceuticals USA, Inc.61$9,267
Ipsen Biopharmaceuticals, Inc80$8,710
AbbVie(2 entities)195$3,564
Lundbeck LLC26$1,697
Merz Pharmaceuticals, LLC44$1,368
Pfizer62$824
Novartis35$637
Lilly USA, LLC42$633
Merz North America, Inc.25$589
Revance Therapeutics, Inc.10$531
Biohaven Pharmaceutical Holding Company Ltd.25$503
Biogen21$421
Bristol Myers Squibb10$420
Biohaven Pharmaceuticals, Inc.26$402
Supernus Pharmaceuticals, Inc.21$376
MDD US Operations, LLC21$327
Bausch Health US, LLC12$300
UCB, Inc.19$294
Avanir Pharmaceuticals, Inc.21$270
Genentech USA, Inc.10$232
Sanofi10$179
Axsome Therapeutics, Inc.6$175
Upsher-smith Laboratories LLC8$168
EMD Serono, Inc.7$166
Assertio Therapeutics, Inc.17$148
Inspire Medical Systems, Inc.3$122
Grifols USA, LLC6$108
Endo Pharmaceuticals Inc.7$108
Otsuka America Pharmaceutical, Inc.5$93
Currax Pharmaceuticals LLC6$87
AstraZeneca4$82
TG Therapeutics, Inc.3$75
SK Life Science, Inc.3$66
Zyla Life Sciences, Inc.3$65
Vertiflex, Inc.1$59
Harmony Biosciences LLC3$50
Takeda Pharmaceuticals U.S.A., Inc.2$43
Optinose US, Inc.2$42
GE HealthCare3$41
Scilex Pharmaceuticals Inc.2$39
Argenx US, Inc.1$32
Abbott2$31
Mallinckrodt Enterprises LLC2$31
Vertical Pharmaceuticals, LLC2$28
Shire North American Group Inc2$27
Livanova USA, Inc.1$26
Xeris Pharmaceuticals, Inc.2$26
Amneal Pharmaceuticals LLC2$25
GRT US Holding, Inc.2$24
Merck1$21
Azurity Pharmaceuticals, Inc.1$21
Eisai Inc.1$18
Neurelis, Inc.1$17
Vertex1$16
Integra Lifesciences Corporation1$14
Impel Pharmaceuticals Inc.1$13
Arbor Pharmaceuticals, Inc.1$12
E.r. Squibb & Sons, L.L.C.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$103,280 in reported general payments places this provider in the 85th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$420,298
Medicare patients
99
Services billed
50,089

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Duloxetine Hcl12$303
Gabapentin11$55

Paid to pharmacies, not to this prescriber.

Other neurology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →